

## **Tissue Regeneration Therapeutics Grants Exclusive License for Perivascular Umbilical Cord Stromal/Stem Cell Technology for Family Banking**

**Toronto, Canada, February 16<sup>th</sup> 2016:** Tissue Regeneration Therapeutics (TRT) announced today an exclusive licensing agreement in the United Kingdom, most of Continental Europe, Ireland, Iceland, UAE, Kuwait, Qatar, Oman, Bahrain, Jordan, and Lebanon. The licensee will now be able to offer families the ability to store and extract stem cells from the tissue surrounding the vessels of the umbilical cord, a rich source of mesenchymal stromal/stem cells (MSCs). The proprietary extraction method is enabled through TRT's human umbilical cord perivascular cell (HUCPVC) patented technology. The licensee plans on a commercial launch in the third quarter of this year.

**TRT** is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP family of cell therapy products. TRT has discovered the world's richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal cells within the harvested population, their increased biological potential compared to cells derived from adult tissues and their inexhaustible supply.

### **About TRT**

TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP cell therapy products. TRT is the only company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the regenerative medicine, defense, and cord banking sectors. Additional information is available at <http://www.verypowerfulbiology.com>